From the Journals

ICYMI: Fingolimod effective in pediatric relapsing multiple sclerosis


 

FROM THE NEW ENGLAND JOURNAL OF MEDICINE

Fingolimod reduced the rate of relapse as well as the deposition of lesions on MRI better than interferon beta-1a did over 2 years in pediatric patients with relapsing multiple sclerosis, according to the results of the PARADIGMS trial, published online Sept. 12 in the New England Journal of Medicine (2018; 379:1017-27. doi: 10.1056/NEJMoa1800149). More serious adverse events were seen in fingolimod-treated patients.

We covered the story before it was published in the journal. Find our conference coverage at the links below.

Next Article:

   Comments ()